Literature DB >> 6304295

Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with 3H-nimodipine radioligand binding.

H Glossmann, D R Ferry, F Lübbecke, R Mewes, F Hofmann.   

Abstract

3H-Nimodipine (3H-NIM) is a high affinity radioligand suitable to study Ca2+ -channels in a variety of tissues. The binding is saturable, reversible, and stereospecific in purified bovine heart and partially purified guinea-pig brain membranes. In the latter a Bmax of 600fmol/mg protein, dissociation constants (KD) of 0.4-0.8nM and a Hill slope of 1.0 are found. At 37 degrees C the optimal pH in 50mM TRIS-HCl buffer is 7.1-7.4. The calcium channel is a metalloprotein, and the divalent cation which is essential for the binding of 3H-NIM can be removed by EDTA (EC50 20 microM); the nimodipine binding site of the channel may then be reconstituted by divalent cations with Mn2+ greater than Ca2+ greater than Mg2+ greater than Sr2+. Ca2+ -antagonist drugs can be divided into three main classes based on their interaction with the 3H-NIM binding site: Class I has one site law of mass action-displacement isotherms with 3H-NIM, Class II exhibits complex biphasic inhibition profiles and Class III drugs increase the affinity of 1,4 dihydropyridines for the Ca2+ -channel. Diltiazem is a Class III Ca2+ -antagonist. Our in vitro studies lead us to conclude that the Ca2+ -channel contains multiple regulatory sites at which drugs can act.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304295     DOI: 10.3109/10799898309041932

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  11 in total

Review 1.  The molecular pharmacology and structural features of calcium channels.

Authors:  D R Ferry; A Goll; M Rombusch; H Glossmann
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 2.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

3.  Purification of the putative calcium channel from skeletal muscle with the aid of [3H]-nimodipine binding.

Authors:  H Glossmann; D R Ferry; C B Boschek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

4.  Correlation between the negative inotropic potency and binding parameters of 1,4-dihydropyridine and phenylalkylamine calcium channel blockers in cat heart.

Authors:  A Goll; H Glossmann; R Mannhold
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

5.  Interaction of calcium channel blockers with non-neuronal benzodiazepine binding sites.

Authors:  E H Cantor; A Kenessey; G Semenuk; S Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

6.  Evidence of multiple receptor sites within the putative calcium channel.

Authors:  D R Ferry; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

7.  Characterization of [3H]-nitrendipine binding to uterine smooth muscle plasma membrane and its relevance to inhibition of calcium entry.

Authors:  S Batra
Journal:  Br J Pharmacol       Date:  1985-08       Impact factor: 8.739

8.  Interactions between diltiazem and ethanol: differences from those seen with dihydropyridine calcium channel antagonists.

Authors:  W P Watson; H J Little
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

9.  Selectivity of Ca2+ channel blockers in inhibiting muscular and nerve activities in isolated colon.

Authors:  S Lecchini; M Marcoli; F De Ponti; C A Castelletti; G M Frigo
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

10.  Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells.

Authors:  W H Barry; J D Horowitz; T W Smith
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.